CYP2C192 and 17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome
Objectives The present study was designed to assess the effect of genetic variants on chronic biological response to prasugrel and bleeding complications. Background CYP2C19*2 loss-of-function allele and CYP2C19*17 gain-of-function allele have been linked with response to clopidogrel, but preliminar...
Gespeichert in:
| Veröffentlicht in: | JACC. Cardiovascular interventions 2012-12, Vol.5 (12), p.1280-1287 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1287 |
|---|---|
| container_issue | 12 |
| container_start_page | 1280 |
| container_title | JACC. Cardiovascular interventions |
| container_volume | 5 |
| creator | Cuisset, Thomas, MD, PhD Loosveld, Marie, MD Morange, Pierre Emmanuel, MD, PhD Quilici, Jacques, MD Moro, Pierre Julien, MD Saut, Noémie, PhD Gaborit, Bénédicte, MD Castelli, Christel, PhD Beguin, Shirley, PhD Grosdidier, Charlotte, MD Fourcade, Laurent, MD Bonnet, Jean-Louis, MD Alessi, Marie-Christine, MD, PhD |
| description | Objectives The present study was designed to assess the effect of genetic variants on chronic biological response to prasugrel and bleeding complications. Background CYP2C19*2 loss-of-function allele and CYP2C19*17 gain-of-function allele have been linked with response to clopidogrel, but preliminary data did not show any significant influence of these alleles on prasugrel effect. Methods A total of 213 patients undergoing successful coronary stenting for acute coronary syndrome and discharged with prasugrel 10 mg daily were included. Prasugrel response was assessed at 1 month with the platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) and high on-treatment platelet reactivity (HTPR) defined as PRI VASP > 50% and hyper-response as PRI VASP |
| doi_str_mv | 10.1016/j.jcin.2012.07.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_inserm_00771418v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1936879812009296</els_id><sourcerecordid>1273402407</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3375-c32b58b2a994dbdcecef64a379a84bfaa63ce298c896e1abb1a8e3234fe9f6e83</originalsourceid><addsrcrecordid>eNp9ks1uEzEUhUcIREvhBVggL1mQ4J_JeCwhpDCipFIkoqYIsbI8njupU4-d2p5IeZS-LQ4pXbBgY3vxnSPfc25RvCV4SjCpPm6nW23clGJCp5hPMZk9K85JzasJr_DseX4LVk1qLuqz4lWMW4wrLDh9WZxRRmeccX5ePDS_VrQhgiLlOkQ4mlsLFiJaqD0ghdZm40xvtHIJXQ07pRPyDq2sSplK6BrizrsIf9RfLEBn3AZdm3iHTMZUMuBSRDcBsqBDP026Raug4rgJYNG8TxDQXI8JUOODdyoc0PrguuAHeF286JWN8Obxvih-XH69aRaT5fdvV818OdGM8Vk-aTurW6qEKLu206Chr0rFuFB12fZKVUwDFbWuRQVEtS1RNTDKyh5EX0HNLooPJ99bZeUumCF_Qnpl5GK-lCbPFgaJMeekJPWeZPz9Cd8Ffz9CTHIwUYO1yoEfoySUsxLTEvOM0hOqg48xQP9kT7A8Nii38tigPDYoMZe5wSx69-g_tgN0T5K_lWXg0wmAHMreQJBR55R1jj6ATrLz5v_-n_-Ra2tcLtjewQHi1o_B5bglkTFr5Pq4Q8cVIhRjQUXFfgMXz8Gw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273402407</pqid></control><display><type>article</type><title>CYP2C192 and 17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Cuisset, Thomas, MD, PhD ; Loosveld, Marie, MD ; Morange, Pierre Emmanuel, MD, PhD ; Quilici, Jacques, MD ; Moro, Pierre Julien, MD ; Saut, Noémie, PhD ; Gaborit, Bénédicte, MD ; Castelli, Christel, PhD ; Beguin, Shirley, PhD ; Grosdidier, Charlotte, MD ; Fourcade, Laurent, MD ; Bonnet, Jean-Louis, MD ; Alessi, Marie-Christine, MD, PhD</creator><creatorcontrib>Cuisset, Thomas, MD, PhD ; Loosveld, Marie, MD ; Morange, Pierre Emmanuel, MD, PhD ; Quilici, Jacques, MD ; Moro, Pierre Julien, MD ; Saut, Noémie, PhD ; Gaborit, Bénédicte, MD ; Castelli, Christel, PhD ; Beguin, Shirley, PhD ; Grosdidier, Charlotte, MD ; Fourcade, Laurent, MD ; Bonnet, Jean-Louis, MD ; Alessi, Marie-Christine, MD, PhD</creatorcontrib><description>Objectives The present study was designed to assess the effect of genetic variants on chronic biological response to prasugrel and bleeding complications. Background CYP2C19*2 loss-of-function allele and CYP2C19*17 gain-of-function allele have been linked with response to clopidogrel, but preliminary data did not show any significant influence of these alleles on prasugrel effect. Methods A total of 213 patients undergoing successful coronary stenting for acute coronary syndrome and discharged with prasugrel 10 mg daily were included. Prasugrel response was assessed at 1 month with the platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) and high on-treatment platelet reactivity (HTPR) defined as PRI VASP > 50% and hyper-response as PRI VASP <75th percentile (PRI VASP < 17%). CYP2C19*2 and CYP2C19*17 genotyping were performed. Results Carriers of loss-of-function *2 allele had significantly higher PRI VASP than noncarriers (33 ± 15% vs. 27 ± 14%, p = 0.03) and higher rate of HTPR (16% vs. 4%, p = 0.01). Conversely, carriers of *17 gain-of-function allele had significantly lower PRI VASP than noncarriers (25 ± 13% vs. 31 ± 15%, p = 0.03, p = 0.03), lower rate of HTPR (1% vs. 10%, p = 0.02), higher rate of hyper-response (34% vs. 21%, p = 0.02), and higher rate of bleeding complications than noncarriers: 23% versus 11%, (odds ratio [95% confidence interval]: 2.5 [1.2 to 5.4]; p = 0.02). No significant influence of genotypes on platelet reactivity assessed by adenosine diphosphate–induced platelet aggregation was observed. Conclusions The present study shows a significant influence of CYP2C19*2 and *17 alleles on response to chronic treatment by prasugrel 10 mg daily and occurrence of bleeding complications.</description><identifier>ISSN: 1936-8798</identifier><identifier>EISSN: 1876-7605</identifier><identifier>DOI: 10.1016/j.jcin.2012.07.015</identifier><identifier>PMID: 23257377</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>acute coronary syndrome ; Acute Coronary Syndrome - surgery ; Alleles ; Aryl Hydrocarbon Hydroxylases - genetics ; bleeding ; Blood Platelets - drug effects ; Blood Platelets - physiology ; Cardiology and cardiovascular system ; Cardiovascular ; Cytochrome P-450 CYP2C19 ; Female ; genotyping ; Hemorrhage - chemically induced ; Hemorrhage - genetics ; Human health and pathology ; Humans ; Life Sciences ; Male ; Middle Aged ; Piperazines - adverse effects ; Piperazines - pharmacology ; Piperazines - therapeutic use ; platelet testing ; Postoperative Complications - chemically induced ; Postoperative Complications - genetics ; prasugrel ; Prasugrel Hydrochloride ; Prospective Studies ; Risk Factors ; Thiophenes - adverse effects ; Thiophenes - pharmacology ; Thiophenes - therapeutic use</subject><ispartof>JACC. Cardiovascular interventions, 2012-12, Vol.5 (12), p.1280-1287</ispartof><rights>American College of Cardiology Foundation</rights><rights>2012 American College of Cardiology Foundation</rights><rights>Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3375-c32b58b2a994dbdcecef64a379a84bfaa63ce298c896e1abb1a8e3234fe9f6e83</citedby><cites>FETCH-LOGICAL-c3375-c32b58b2a994dbdcecef64a379a84bfaa63ce298c896e1abb1a8e3234fe9f6e83</cites><orcidid>0000-0002-8372-4148 ; 0000-0003-3927-5792</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcin.2012.07.015$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23257377$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-00771418$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Cuisset, Thomas, MD, PhD</creatorcontrib><creatorcontrib>Loosveld, Marie, MD</creatorcontrib><creatorcontrib>Morange, Pierre Emmanuel, MD, PhD</creatorcontrib><creatorcontrib>Quilici, Jacques, MD</creatorcontrib><creatorcontrib>Moro, Pierre Julien, MD</creatorcontrib><creatorcontrib>Saut, Noémie, PhD</creatorcontrib><creatorcontrib>Gaborit, Bénédicte, MD</creatorcontrib><creatorcontrib>Castelli, Christel, PhD</creatorcontrib><creatorcontrib>Beguin, Shirley, PhD</creatorcontrib><creatorcontrib>Grosdidier, Charlotte, MD</creatorcontrib><creatorcontrib>Fourcade, Laurent, MD</creatorcontrib><creatorcontrib>Bonnet, Jean-Louis, MD</creatorcontrib><creatorcontrib>Alessi, Marie-Christine, MD, PhD</creatorcontrib><title>CYP2C192 and 17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome</title><title>JACC. Cardiovascular interventions</title><addtitle>JACC Cardiovasc Interv</addtitle><description>Objectives The present study was designed to assess the effect of genetic variants on chronic biological response to prasugrel and bleeding complications. Background CYP2C19*2 loss-of-function allele and CYP2C19*17 gain-of-function allele have been linked with response to clopidogrel, but preliminary data did not show any significant influence of these alleles on prasugrel effect. Methods A total of 213 patients undergoing successful coronary stenting for acute coronary syndrome and discharged with prasugrel 10 mg daily were included. Prasugrel response was assessed at 1 month with the platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) and high on-treatment platelet reactivity (HTPR) defined as PRI VASP > 50% and hyper-response as PRI VASP <75th percentile (PRI VASP < 17%). CYP2C19*2 and CYP2C19*17 genotyping were performed. Results Carriers of loss-of-function *2 allele had significantly higher PRI VASP than noncarriers (33 ± 15% vs. 27 ± 14%, p = 0.03) and higher rate of HTPR (16% vs. 4%, p = 0.01). Conversely, carriers of *17 gain-of-function allele had significantly lower PRI VASP than noncarriers (25 ± 13% vs. 31 ± 15%, p = 0.03, p = 0.03), lower rate of HTPR (1% vs. 10%, p = 0.02), higher rate of hyper-response (34% vs. 21%, p = 0.02), and higher rate of bleeding complications than noncarriers: 23% versus 11%, (odds ratio [95% confidence interval]: 2.5 [1.2 to 5.4]; p = 0.02). No significant influence of genotypes on platelet reactivity assessed by adenosine diphosphate–induced platelet aggregation was observed. Conclusions The present study shows a significant influence of CYP2C19*2 and *17 alleles on response to chronic treatment by prasugrel 10 mg daily and occurrence of bleeding complications.</description><subject>acute coronary syndrome</subject><subject>Acute Coronary Syndrome - surgery</subject><subject>Alleles</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>bleeding</subject><subject>Blood Platelets - drug effects</subject><subject>Blood Platelets - physiology</subject><subject>Cardiology and cardiovascular system</subject><subject>Cardiovascular</subject><subject>Cytochrome P-450 CYP2C19</subject><subject>Female</subject><subject>genotyping</subject><subject>Hemorrhage - chemically induced</subject><subject>Hemorrhage - genetics</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - pharmacology</subject><subject>Piperazines - therapeutic use</subject><subject>platelet testing</subject><subject>Postoperative Complications - chemically induced</subject><subject>Postoperative Complications - genetics</subject><subject>prasugrel</subject><subject>Prasugrel Hydrochloride</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Thiophenes - adverse effects</subject><subject>Thiophenes - pharmacology</subject><subject>Thiophenes - therapeutic use</subject><issn>1936-8798</issn><issn>1876-7605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks1uEzEUhUcIREvhBVggL1mQ4J_JeCwhpDCipFIkoqYIsbI8njupU4-d2p5IeZS-LQ4pXbBgY3vxnSPfc25RvCV4SjCpPm6nW23clGJCp5hPMZk9K85JzasJr_DseX4LVk1qLuqz4lWMW4wrLDh9WZxRRmeccX5ePDS_VrQhgiLlOkQ4mlsLFiJaqD0ghdZm40xvtHIJXQ07pRPyDq2sSplK6BrizrsIf9RfLEBn3AZdm3iHTMZUMuBSRDcBsqBDP026Raug4rgJYNG8TxDQXI8JUOODdyoc0PrguuAHeF286JWN8Obxvih-XH69aRaT5fdvV818OdGM8Vk-aTurW6qEKLu206Chr0rFuFB12fZKVUwDFbWuRQVEtS1RNTDKyh5EX0HNLooPJ99bZeUumCF_Qnpl5GK-lCbPFgaJMeekJPWeZPz9Cd8Ffz9CTHIwUYO1yoEfoySUsxLTEvOM0hOqg48xQP9kT7A8Nii38tigPDYoMZe5wSx69-g_tgN0T5K_lWXg0wmAHMreQJBR55R1jj6ATrLz5v_-n_-Ra2tcLtjewQHi1o_B5bglkTFr5Pq4Q8cVIhRjQUXFfgMXz8Gw</recordid><startdate>201212</startdate><enddate>201212</enddate><creator>Cuisset, Thomas, MD, PhD</creator><creator>Loosveld, Marie, MD</creator><creator>Morange, Pierre Emmanuel, MD, PhD</creator><creator>Quilici, Jacques, MD</creator><creator>Moro, Pierre Julien, MD</creator><creator>Saut, Noémie, PhD</creator><creator>Gaborit, Bénédicte, MD</creator><creator>Castelli, Christel, PhD</creator><creator>Beguin, Shirley, PhD</creator><creator>Grosdidier, Charlotte, MD</creator><creator>Fourcade, Laurent, MD</creator><creator>Bonnet, Jean-Louis, MD</creator><creator>Alessi, Marie-Christine, MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier/American College of Cardiology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-8372-4148</orcidid><orcidid>https://orcid.org/0000-0003-3927-5792</orcidid></search><sort><creationdate>201212</creationdate><title>CYP2C192 and 17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome</title><author>Cuisset, Thomas, MD, PhD ; Loosveld, Marie, MD ; Morange, Pierre Emmanuel, MD, PhD ; Quilici, Jacques, MD ; Moro, Pierre Julien, MD ; Saut, Noémie, PhD ; Gaborit, Bénédicte, MD ; Castelli, Christel, PhD ; Beguin, Shirley, PhD ; Grosdidier, Charlotte, MD ; Fourcade, Laurent, MD ; Bonnet, Jean-Louis, MD ; Alessi, Marie-Christine, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3375-c32b58b2a994dbdcecef64a379a84bfaa63ce298c896e1abb1a8e3234fe9f6e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>acute coronary syndrome</topic><topic>Acute Coronary Syndrome - surgery</topic><topic>Alleles</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>bleeding</topic><topic>Blood Platelets - drug effects</topic><topic>Blood Platelets - physiology</topic><topic>Cardiology and cardiovascular system</topic><topic>Cardiovascular</topic><topic>Cytochrome P-450 CYP2C19</topic><topic>Female</topic><topic>genotyping</topic><topic>Hemorrhage - chemically induced</topic><topic>Hemorrhage - genetics</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - pharmacology</topic><topic>Piperazines - therapeutic use</topic><topic>platelet testing</topic><topic>Postoperative Complications - chemically induced</topic><topic>Postoperative Complications - genetics</topic><topic>prasugrel</topic><topic>Prasugrel Hydrochloride</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Thiophenes - adverse effects</topic><topic>Thiophenes - pharmacology</topic><topic>Thiophenes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cuisset, Thomas, MD, PhD</creatorcontrib><creatorcontrib>Loosveld, Marie, MD</creatorcontrib><creatorcontrib>Morange, Pierre Emmanuel, MD, PhD</creatorcontrib><creatorcontrib>Quilici, Jacques, MD</creatorcontrib><creatorcontrib>Moro, Pierre Julien, MD</creatorcontrib><creatorcontrib>Saut, Noémie, PhD</creatorcontrib><creatorcontrib>Gaborit, Bénédicte, MD</creatorcontrib><creatorcontrib>Castelli, Christel, PhD</creatorcontrib><creatorcontrib>Beguin, Shirley, PhD</creatorcontrib><creatorcontrib>Grosdidier, Charlotte, MD</creatorcontrib><creatorcontrib>Fourcade, Laurent, MD</creatorcontrib><creatorcontrib>Bonnet, Jean-Louis, MD</creatorcontrib><creatorcontrib>Alessi, Marie-Christine, MD, PhD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>JACC. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cuisset, Thomas, MD, PhD</au><au>Loosveld, Marie, MD</au><au>Morange, Pierre Emmanuel, MD, PhD</au><au>Quilici, Jacques, MD</au><au>Moro, Pierre Julien, MD</au><au>Saut, Noémie, PhD</au><au>Gaborit, Bénédicte, MD</au><au>Castelli, Christel, PhD</au><au>Beguin, Shirley, PhD</au><au>Grosdidier, Charlotte, MD</au><au>Fourcade, Laurent, MD</au><au>Bonnet, Jean-Louis, MD</au><au>Alessi, Marie-Christine, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CYP2C192 and 17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome</atitle><jtitle>JACC. Cardiovascular interventions</jtitle><addtitle>JACC Cardiovasc Interv</addtitle><date>2012-12</date><risdate>2012</risdate><volume>5</volume><issue>12</issue><spage>1280</spage><epage>1287</epage><pages>1280-1287</pages><issn>1936-8798</issn><eissn>1876-7605</eissn><abstract>Objectives The present study was designed to assess the effect of genetic variants on chronic biological response to prasugrel and bleeding complications. Background CYP2C19*2 loss-of-function allele and CYP2C19*17 gain-of-function allele have been linked with response to clopidogrel, but preliminary data did not show any significant influence of these alleles on prasugrel effect. Methods A total of 213 patients undergoing successful coronary stenting for acute coronary syndrome and discharged with prasugrel 10 mg daily were included. Prasugrel response was assessed at 1 month with the platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) and high on-treatment platelet reactivity (HTPR) defined as PRI VASP > 50% and hyper-response as PRI VASP <75th percentile (PRI VASP < 17%). CYP2C19*2 and CYP2C19*17 genotyping were performed. Results Carriers of loss-of-function *2 allele had significantly higher PRI VASP than noncarriers (33 ± 15% vs. 27 ± 14%, p = 0.03) and higher rate of HTPR (16% vs. 4%, p = 0.01). Conversely, carriers of *17 gain-of-function allele had significantly lower PRI VASP than noncarriers (25 ± 13% vs. 31 ± 15%, p = 0.03, p = 0.03), lower rate of HTPR (1% vs. 10%, p = 0.02), higher rate of hyper-response (34% vs. 21%, p = 0.02), and higher rate of bleeding complications than noncarriers: 23% versus 11%, (odds ratio [95% confidence interval]: 2.5 [1.2 to 5.4]; p = 0.02). No significant influence of genotypes on platelet reactivity assessed by adenosine diphosphate–induced platelet aggregation was observed. Conclusions The present study shows a significant influence of CYP2C19*2 and *17 alleles on response to chronic treatment by prasugrel 10 mg daily and occurrence of bleeding complications.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23257377</pmid><doi>10.1016/j.jcin.2012.07.015</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8372-4148</orcidid><orcidid>https://orcid.org/0000-0003-3927-5792</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1936-8798 |
| ispartof | JACC. Cardiovascular interventions, 2012-12, Vol.5 (12), p.1280-1287 |
| issn | 1936-8798 1876-7605 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_inserm_00771418v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | acute coronary syndrome Acute Coronary Syndrome - surgery Alleles Aryl Hydrocarbon Hydroxylases - genetics bleeding Blood Platelets - drug effects Blood Platelets - physiology Cardiology and cardiovascular system Cardiovascular Cytochrome P-450 CYP2C19 Female genotyping Hemorrhage - chemically induced Hemorrhage - genetics Human health and pathology Humans Life Sciences Male Middle Aged Piperazines - adverse effects Piperazines - pharmacology Piperazines - therapeutic use platelet testing Postoperative Complications - chemically induced Postoperative Complications - genetics prasugrel Prasugrel Hydrochloride Prospective Studies Risk Factors Thiophenes - adverse effects Thiophenes - pharmacology Thiophenes - therapeutic use |
| title | CYP2C192 and 17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T08%3A33%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CYP2C192%20and%2017%20Alleles%20Have%20a%20Significant%20Impact%20on%20Platelet%20Response%20and%20Bleeding%20Risk%20in%20Patients%20Treated%20With%20Prasugrel%20After%20Acute%20Coronary%20Syndrome&rft.jtitle=JACC.%20Cardiovascular%20interventions&rft.au=Cuisset,%20Thomas,%20MD,%20PhD&rft.date=2012-12&rft.volume=5&rft.issue=12&rft.spage=1280&rft.epage=1287&rft.pages=1280-1287&rft.issn=1936-8798&rft.eissn=1876-7605&rft_id=info:doi/10.1016/j.jcin.2012.07.015&rft_dat=%3Cproquest_hal_p%3E1273402407%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273402407&rft_id=info:pmid/23257377&rft_els_id=S1936879812009296&rfr_iscdi=true |